Accepted Manuscript

Title: Management of MDR-TB in HIV co-infected patients in eastern europe: results from the TB:HIV study

Author: A.M. W. Efsen, A. Schultze, R.F. Miller, A. Panteleev, A. Skrahin, D.N. Podlekareva, J.M. Miro, E. Girardi, H. Furrer, M.H. Losso, J. Toibaro, J.A. Caylà, A. Mocroft, J.D. Lundgren, F.A. Post, O. Kirk, TB: HIV study in EuroCoord

PII: S0163-4453(17)30320-1
DOI: <https://doi.org/doi:10.1016/j.jinf.2017.10.007>
Reference: YJINF 4002

To appear in: *Journal of Infection*

Accepted date: 7-10-2017

Please cite this article as: A.M. W. Efsen, A. Schultze, R.F. Miller, A. Panteleev, A. Skrahin, D.N. Podlekareva, J.M. Miro, E. Girardi, H. Furrer, M.H. Losso, J. Toibaro, J.A. Caylà, A. Mocroft, J.D. Lundgren, F.A. Post, O. Kirk, TB: HIV study in EuroCoord, Management of MDR-TB in HIV co-infected patients in eastern europe: results from the TB:HIV study, *Journal of Infection* (2017), <https://doi.org/doi:10.1016/j.jinf.2017.10.007>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Title**

2 Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

3 **Running Title**

4 Management of HIV-positive patients with MDR-TB in Eastern Europe

5 **Authors**

6 A.M. W. Efsen^{1,*}, A. Schultze², R.F. Miller³, A. Panteleev⁴, A. Skrahin⁵, D.N. Podlekareva¹, J.M. Miro⁶, E.
 7 Girardi⁷, H. Furrer⁸, M.H. Losso⁹, J. Toibaro⁹, J. A. Caylà¹⁰, A. Mocroft², J.D. Lundgren¹, F.A. Post¹¹, O. Kirk¹,
 8 for the TB:HIV study in EuroCoord[#]

9 [#]A full list of the TB:HIV Study Group investigators can be found in the acknowledgement section

10

11 **Affiliations**

12 ¹CHIP, Department of Infectious Diseases, Finsencentret, Rigshospitalet, University of Copenhagen,
 13 Blegdamsvej 9, 2100 Copenhagen Ø, Denmark (Anne Marie Werlinrud Efsen (PhD), Daria N.
 14 Podlekareva (MD), Jens D. Lundgren (DMSc), Ole Kirk (DMSc)).

15 ²Department of Infection and Population Health, University College London Medical School, Rowland
 16 Hill Street, NW3 2PF, London, UK ((Anna Schultze (MSc), Amanda Mocroft (Professor)).

17 ³Centre for Sexual Health and HIV Research, Mortimer Market Centre, University College London,
 18 London WC1E 6JB, UK (Robert F. MILLER (Professor))

19 ⁴Department of HIV/TB, TB hospital 2, Ushinskogo str 39/1 – 122, 195267 St. Petersburg, Russia
 20 (Alexander Panteleev (DMSc))

21 ⁵Clinical Department, Republican Research and Practical Centre for Pulmonology and TB, Minsk,
 22 Belarus (Aliaksandr Skrahin (MD))

23 ⁶Infectious Diseases Service, Hospital Clinic – IDIBAPS. University of Barcelona, Villarroel, 170, 08036
 24 Barcelona, Spain (Jose M. Miro (PhD))

25 ⁷Department of Infectious Diseases INMI "L. Spallanzani", Ospedale L Spallanzani, Via Portuense, 292,
 26 00149 Rome, Italy (Enrico Girardi (MD))

27 ⁸Department of Infectious Diseases, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
 28 (Hansjakob Furrer (Professor))

29 ⁹Department of immunocompromised, Hospital J.M. Ramos Mejia, Pabellón de Clínica, 2do Piso, CP
 30 1221 Buenos Aires, Argentina (Marcelo H. Losso (MD), Javier Toibaro (MD))

¹⁰Agencia de Salud Pública de Barcelona, Barcelona, España; Programa Integrado de Investigación en Tuberculosis de SEPAR (PII-TB); Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP) (Joan A. Caylà, (MD))

¹¹Department of Sexual Health, Caldecot Centre, King's College Hospital, Bessemer Road, London SE5 9RS, UK (Frank A. POST (MD))

***Corresponding Author**

Anne Marie Werlinrud Efsen, PhD

Rigshospitalet, University of Copenhagen

CHIP, Department of Infectious Diseases, Section 2100 (CHIP)

Blegdamsvej 9

DK-2100 Copenhagen Ø, Denmark

Phone: + 45 35 45 57 57

Fax: +45 35 45 57 58

E-mail: [anne.marie.werlinrud.efsen@regionh.dk/](mailto:anne.marie.werlinrud.efsen@regionh.dk)

Web: www.chip.dk

Keywords

Tuberculosis; HIV; MDR-TB; Eastern Europe

Word count manuscript: 2735; **word count abstract:** 200

Conference presentation

The results from this study were presented as a poster at the TB2016 conference, 16-17 July, Durban, South Africa (www.tb2016.org). Poster "Management of TB/HIV Co-infected Patients Including MDR-TB in Eastern Europe: Results from the TB:HIV Study", number: P37.

Highlights

- Management of TB/HIV co-infected patients in Eastern Europe (EE) is suboptimal
- TB/HIV co-infected patients diagnosed with MDR-TB received inferior TB treatment with limited numbers of active drugs
- Access to rapid diagnostics for TB is urgently needed
- Performance of extended DST for all patients diagnosed with MDR-TB is required
- Integration of TB and HIV clinics can potentially ensure better management of patients in EE

Abstract

Objectives

Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce.

Methods

In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART).

Results

A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%.

Conclusions

Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of

patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care.

Introduction

Although rates of tuberculosis (TB) have begun to decline in recent years, simultaneous rapid increases in the relative contribution of multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) are worrying (1-4). Eastern Europe (EE), together with central Asia, has the worlds' highest proportions of MDR- and XDR-TB with 9-35% of new TB cases and 49-77% of re-treatment cases being diagnosed with MDR-TB in Belarus, Russia and Ukraine compared with 1-3% of new cases and 4-14% of re-treatment cases in Italy, Switzerland and the United Kingdom (1, 5-8).

The MDR-TB epidemic in EE is further complicated by high rates of HIV co-infection. Whereas most other regions have reported declining rates of new HIV infections over recent years, EE has experienced an increase of 30% in annual number of new HIV infections since the turn of the millennium (9, 10). The TB/HIV epidemic in EE is primarily driven by injection drug users (IDU) who often access health care late, are co-infected with hepatitis C (HCV), and frequently have poor treatment compliance and retention in care (11-14). We recently reported a one-year mortality rate of 27% for TB/HIV co-infected patients in EE, and patients diagnosed with MDR-TB had roughly three-times higher mortality compared to those with drug-susceptible TB. Further, patients from EE who initiated TB treatment with three or more active drugs had significantly lower risk of death compared to patients who received less than three active TB drugs (13% vs 34%) (15).

Treatment for MDR-TB is complex in terms of pill burden, drug-interactions and toxicity, and costly (1, 16-18). MDR-TB therapy is prolonged (typically at least 20 months) although the 2016 WHO guidelines include

an option for shorter MDR-TB regimens in specific cases (16, 19). Preliminary results with a novel six months regimen (consisting of pretomanid, bedaquiline and linezolid) may be highly effective to treat MDR-TB (20). For now, standard of care consists of at least five drugs including a fluoroquinolone, a second-line injectable, at least two other active drugs plus pyrazinamide during the intensive phase of treatment (19). Reported MDR-TB treatment success rates, however, have been generally low, in particular for HIV-positive individuals, and rarely exceed 50% (18, 21).

Epidemiological data and detailed descriptions of the clinical management of HIV-positive patients with MDR-TB in EE remain relatively scarce (22). We prospectively studied patients with TB/HIV co-infection in EE and in this paper report on the management of those with MDR-TB.

Methods

Study design and participants

The TB:HIV Study is a prospective cohort study including 62 TB and HIV clinics in 19 countries in EE, Western Europe, Southern Europe, and Latin America. Adult (>16 years) HIV-positive patients with a TB diagnosis were consecutively enrolled between 01/01/2011 and 31/12/2013. Demographic, clinical, and laboratory data were collected on standardized case report forms at baseline and month 6, 12, and 24 (12); further details are available at <http://www.cphiv.dk/TBHIV>. All participating clinics obtained ethical approval in accordance with local rules and legislations, and the study was performed in accordance with the strobe guidelines for observational studies (23).

Study definitions

Patients from EE were included in the present analyses if they had definite or probable TB. A diagnosis of definite TB was based on positive culture or molecular diagnostics for *Mycobacterium tuberculosis* (*Mtb*),

and probable TB on the presence of acid fast bacilli and/or granulomatous inflammation on sputum smear or tissue biopsy specimens (12). **Baseline** was defined as the date TB treatment was initiated, and a baseline culture was defined as a culture obtained within one month of baseline. All TB drugs initiated within 10 days of baseline were considered to constitute initial TB treatment. Standard definitions of MDR-TB, pre-XDR-TB, and XDR-TB were used (see box), and pan-susceptible TB was defined as TB without documented drug resistance. TB treatment regimens were categorized in line with general recommendations (16, 24): 1: Treatment regimens containing RHZ (with or without ES) targeting drug-susceptible TB (24), 2: Treatment regimens containing RHZ plus a fluoroquinolone AND a second line injectable, providing empiric cover for both susceptible TB and MDR-TB, 3: Five or more MDR-TB drugs (including a fluoroquinolone AND a second line injectable) providing appropriate empiric cover for MDR-TB, 4: Regimens containing a fluoroquinolone OR a second line injectable (but not both), providing inadequate cover for MDR-TB, and 5: Any other drug combination (Fig. 1). For patients with MDR-TB, the number of active drugs in the TB regimen was calculated at various time points based on the susceptibility pattern of isolates obtained up to the given time point. If a Drug Susceptibility Test (DST) result was not available for a specific drug included in the regimen, the given *Mtb* isolate was either considered potentially susceptible to this drug (**potentially** active drugs) or resistant to this drug (**known** active drugs), thus representing a “best case” and “worst case” treatment scenario.

Antiretroviral treatment (ART) was defined as a combination of ≥ 3 antiretroviral drugs from any ART class. Participants were considered **lost to follow-up** (LTFU) when no attendance was recorded at the relevant time points in those who were not known to have died.

Statistical analysis

Descriptive statistics were used for baseline characteristics of patients. Patients were stratified into three groups: MDR-TB at baseline, pan-susceptible TB at baseline, and other (no baseline DST results available or the presence of non-MDR-TB resistance patterns). MDR-TB patients who had extended DST available were

further classified as having pre-XDR or XDR-TB. Baseline characteristics among patients who had MDR-TB, those who were fully susceptible and those who did not have any baseline DST available were compared using the chi-squared test or Fisher's exact test as appropriate for categorical variables, whereas the Kruskal-Wallis test was used to compare continuous variables.

TB and HIV treatment regimens were analyzed at months 0, 3, 7, 13, and 21. Kaplan-Meier estimates were used to estimate time to receiving adequate treatment for MDR-TB (category 3: five or more MDR-TB drugs including a fluoroquinolone AND a second line injectable), and time to starting ART censoring at last visit date (maximum 21 months) or death, whichever occurred first. Further, Kaplan-Meier estimates were also used to estimate the time to starting ART. All statistical analyses were performed using SAS (Statistical Analysis Software, Cary, NC, USA, version 9.3).

Results

Patient characteristics

Of 1406 patients enrolled into the TB:HIV study, 834 received care in EE, of these 485 had definite or probable TB and were included in this analysis (supplementary Fig. 1). A positive culture for *Mtb* was reported in 383 (79%) patients, 302 (79%) of these were tested for resistance to any drug, 270 (70%) for both R and H, and 68 (18%) for fluoroquinolone or second line injectables. Of the 485 patients, 105 (22%) had MDR-TB, 130 (27%) had pan-susceptible TB at baseline and 183 (38%) had no DST results; the remaining 67 (14%) had non-MDR-TB resistance patterns and were excluded from subsequent analyses. Baseline characteristics are shown in Table 1. The majority of patients were male and white, with a median age of 35 years. Recent incarceration was common, and previous TB, IDU, and HCV co-infection were significantly more common among MDR-TB patients. The median baseline CD4 cell count was 91 (interquartile range [IQR] 31-230) cells/mm³, and only 82 (17%) patients were on ART.

175 **DST patterns for MDR-TB patients**

176 Among the 105 patients with MDR-TB at baseline, DST results (obtained at any time during TB treatment)
 177 for other drugs ranged from 51-95% for group 1 drugs, 75-78% for group 2/3 drugs, and 49-69% for group 4
 178 drugs (Table 2). The timing of DST testing for individual TB drugs is shown in Table 3a. Overall, 13 (12%) of
 179 MDR-TB patients had XDR-TB, 20 (19%) had pre-XDR, 35 (33%) had MDR, and 37 patients had insufficient
 180 data to determine pre-XDR/XDR-TB status.

181 **Treatment regimen and outcomes**

182 In Fig. 1, TB treatment regimens and outcomes are depicted from baseline through 21 months of follow-up.
 183 WHO recommended regimens were initiated in the majority of individuals with drug-susceptible TB but
 184 maintained well beyond the recommended 6 months. Despite the high population prevalence of MDR-TB,
 185 very few subjects received empiric therapy that provided cover against drug-susceptible and (multi)drug
 186 resistant TB (category 2). High rates of death were observed among MDR-TB patients and those without
 187 DST. Loss to follow-up (from both TB and HIV care) was high, ranging from 8% of MDR-TB patients to 19-
 188 20% among patients with pan-susceptible TB or no DST.

189 **TB treatment for MDR-TB patients**

190 Only 8 (8%) of MDR-TB patients initiated an adequate empiric MDR-TB regimen (category 3), which
 191 increased to 35 (44% of patients still under follow-up) after three months. A total of 49 MDR-TB patients
 192 ever received category 3 treatment after a median of 1.2 months (IQR 0.4-2.3), and by 12 months, an
 193 estimated 57.3% (95%CI=41.5-74.1%) had started adequate MDR-TB treatment. Similar results were
 194 obtained when excluding patients with known pre-XDR-TB or XDR-TB (data not shown).

195 Fluoroquinolones and second-line injectables were uncommon components of initial treatment and, if
 196 used, commonly used without adequate companion drugs (Table 3b/c). By three months, a quarter of
 197 MDR-TB patients still had not initiated a fluoroquinolone or a second-line injectable. Group 4 drugs were

198 variably used, a single patient had received linezolid (introduced late during the course of treatment), and
 199 no patients had received bedaquiline or delamanide. Culture conversion was documented in 45/105 (43%)
 200 of MDR-TB patients and 77/130 (59%) of patients with pan-susceptible TB after a median of 3.0 (IQR 1.8-
 201 5.1) and 2.3 (IQR 1.7-4.9, $p=0.30$) months, respectively.

202 **Activity of TB treatment for MDR-TB patients**

203 Fig. 2a-c illustrates the total number of drugs and the total number of “potentially” active drugs and
 204 “known” active drugs, respectively, in the MDR-TB treatment regimens. While most patients received 4 or
 205 more drugs in their regimen during the first year of treatment, more than 70% received 0, 1 or 2 drugs with
 206 demonstrated activity. A regimen containing 5 or more known active drugs was received by less than 15%
 207 of patients and a regimen containing 5 or more potentially active drugs by less than 40% of patients.

208 **HIV treatment for MDR-TB patients**

209 Despite 77% of MDR-TB patients at the time of their TB diagnosis already having an HIV diagnosis and the
 210 majority being severely immunosuppressed with a median CD4 cell count of 100 cells/mm³, only 13% were
 211 on ART at baseline (Table 1). The proportion on ART among those who remained in care increased to more
 212 than 60% (Figure 3). The majority of those on ART did not have regular HIV-RNA monitoring, and less than
 213 20% of MDR-TB patients were documented to have had an undetectable HIV-RNA (<500 copies/mL) at any
 214 stage during follow up. The Kaplan-Meier estimate of starting ART by eight weeks was only 23%; similar
 215 results were observed for patients with drug-susceptible TB and those with no DST results (data not
 216 shown).

217

218 **Discussion**

219 This study shows suboptimal management of MDR-TB in HIV-positive patients in EE. Despite the high
 220 prevalence of MDR-TB, full DST testing was often restricted and delayed, resulting in prolonged use of
 221 inappropriate or failing regimens that contained few active drugs and suboptimal intensification strategies,
 222 with only half of patients ultimately receiving recommended MDR-TB therapy. In addition, we observed a
 223 low uptake of ART, inadequate viral load monitoring and low rates of HIV-RNA suppression. All of these
 224 factors are likely to have contributed to the mortality rate of nearly 50% at two years. These data point
 225 towards opportunities to improve management of HIV-positive individuals with TB in parts of EE.

226 The similar characteristics of patients with and without MDR-TB preclude public health strategies based on
 227 risk-stratification of patients and argue for routine DST in all TB patients. Rapid TB diagnostics and DST such
 228 as line-probe assays or cartridge-based molecular tests for *Mtb* and rifampicin resistance (16) should be
 229 introduced as a priority (25), with routine evaluation of genotypic or phenotypic DST for fluoroquinolones
 230 and second line injectables of all rifampicin-resistant isolates. Thirty-nine percent of those tested for MDR-
 231 TB in our cohort had MDR-TB which is consistent with other recent reports from the EE region (8, 26). Of
 232 the patients with MDR-TB, approximately one-third had MDR, one-third had pre-XDR or XDR-TB, and one-
 233 third did not have sufficient DST data to assess whether they had (pre-)XDR-TB. We also found common co-
 234 resistance to other drugs, as described in another European multicenter study (27). Despite the setting of
 235 high MDR-TB prevalence in EE, empiric therapy rarely provided cover for MDR-TB. This is also problematic
 236 as selection for additional drug-resistance is more likely to occur early on when the bacillary burden is high.
 237 It is worth noting, however, that four in five patients who later were shown to have fully susceptible TB,
 238 initially received adequate RHZ-based treatment, as recently described (28).

239 In patients with MDR-TB, there were significant delays to initiate treatment for MDR-TB, and many patients
 240 never received adequate MDR-TB treatment as defined by international guidelines (19). The number of
 241 active drugs remained low at all time points; only one-third of patients were treated at some stage with at
 242 least five potentially active drugs, and only one-sixth of patients received regimens with 5 drugs known to

243 have activity against their *Mtb* isolate. This is of concern as recent studies demonstrate improved outcomes
 244 with optimal MDR-TB regimens (≥ 5 likely effective drugs) (29-31). Optimal MDR-TB treatment requires
 245 continued, unrestricted access to high quality medications; in a recent survey we documented that this was
 246 not the case in many clinics in EE (32). In agreement with this, linezolid, bedaquiline and delamanid were
 247 generally not used although widespread use in the current context raises significant opportunities for these
 248 drugs to be rapidly lost due to the emergence of resistance.

249 There is now solid evidence that ART should be initiated shortly after TB diagnosis, especially in patients
 250 with MDR-TB and those with CD4 cell counts below 50 cells/mm³ (33-36). In our study, patients were
 251 severely immunosuppressed, and two-thirds of those who remained under follow-up at three months had
 252 initiated ART. However, less than 20% had documented suppressed viral loads at any time which is well
 253 short of the WHO goal of virological suppression in 90% of patients receiving ART (37).

254 We documented a mortality rate of nearly 50% within the first two years following initiation of TB
 255 treatment, which is similar to the mortality observed in a retrospective study from our group of HIV-
 256 patients with MDR-TB in EE which was conducted in the period 2004-2006 (14). Retrospective African
 257 studies reported mortality rates among HIV-positive patients with MDR-TB of 15-31% (38-40) and a meta-
 258 analysis of outcomes found a pooled mortality rate of 38% (41). The vast majority of deaths in our
 259 retrospective cohort were due to TB (42), which underscores the particular need for high-quality TB
 260 management for people with HIV. Other circumstances may have played a role in determining outcome of
 261 MDR-TB patients in EE. A disintegrated health care system with separated TB and HIV management remains
 262 common (32) and is likely to contribute to poor coordination of care to this often very vulnerable patient
 263 population. In particular, opioid substitution therapy for IDU is severely restricted or even prohibited in
 264 some countries despite documented positive effects on adherence to treatment and health care in general
 265 (43).

Our observational study has several limitations including the intrinsic risk of selection bias. The participating clinics were primarily located in major cities and may not be representative of all clinics across EE. DST was done locally and methods for performing DSTs varied between clinics, and when calculating the number of active drugs, we counted all drugs as equally effective which is likely to be an over-simplification. A large number of patients had missing DST results, CD4 cell counts and HIV-RNA measurements precluding a more robust evaluation of immune-virological outcomes. Nonetheless, the circumstances described reflect the difficulties for many HIV and TB clinicians working in EE, although substantial regional variability in the prevalence of MDR-TB and availability of DST, TB and ART drugs, and HIV-RNA measurements exists (12). Due to limited number of patients with MDR-TB we did not assess intraregional variability.

Conclusion

In EE, there is an urgent need for access to rapid diagnostics to guide initial TB treatment, to extended DST to all patients diagnosed with rifamycin-resistant or MDR-TB and to provide better access to second line drugs to allow the administration of optimally active MDR-TB regimens. Integration of TB and HIV services can ensure better management and support for people with HIV who frequently have IDU and HCV coinfection, including rapid initiation of fully suppressive ART.

Acknowledgements

The TB:HIV Study Group

Eastern Europe

Belarus: Belarusian State Medical University, Department of Infectious Disease: I. Karpov (PI), A. Vassilenko;
Republican Research and Practical Centre for Pulmonology and TB (Minsk): A. Skrahina (PI), D. Klimuk, A.

- 288 Skrahin, O. Kondratenko and A. Zalutskaya; Gomel State Medical University (Gomel): V. Bondarenko (PI), V.
 289 Mitsura, E. Kozorez, O. Tumash; Gomel Region Centre for Hygiene: O. Suetnov (PI) and D. Paduto.
- 290 Estonia: East Viru Central Hospital (Kohtla-Järve): V. Iljina (PI) and T. Kummik.
- 291 Georgia: Infectious Diseases, AIDS and Clinical Immunology Research Center (Tbilisi): N. Bolokadze (PI), K.
 292 Mshvidobadze and N. Lanchava; National Center for Tuberculosis and Lung Diseases of Georgia (Tbilisi): L.
 293 Goginashvili, L. Mikiashvili and N. Bablishvili.
- 294 Latvia: Infectology Centre of Latvia (Riga): B. Rozentale (PI), I. Zeltina and I. Janushkevich.
- 295 Lithuania: Centre for Communicable Diseases and AIDS (Vilnius): I. Caplinskiene (PI), S. Caplinskas, Z.
 296 Kancauskiene.
- 297 Poland: Wojewodski Szpital Zakazny/Medical University of Warsaw (Warszawa): R. Podlasin (PI), A.
 298 Wiercinska-Drapalo (PI), M. Thompson and J. Kozłowska; Wojewodski Szpital Specjalistyczny/Medical
 299 University Teaching Hospital (Białystok): A. Grezesczuk (PI); Józef Strus Multidisciplinary City Hospital
 300 (Poznań): M. Bura (PI); Wrocław University School of Medicine (Wrocław): B. Knysz (PI) and M. Inglot;
 301 Jagiellonian University Medical College (Kraków): A. Garlicki (PI) and J. Loster.
- 302 Romania: Dr. Victor Babes Hospital (Bucharest): S. Tetrarov (PI) and D. Duiculescu (†).
- 303 Russia: Botkin Hospital of Infectious Diseases (St. Petersburg): A. Rakhmanova (PI†), O. Panteleeva, A.
 304 Yakovlev, A. Kozlov, A. Tyukalova and Y. Vlasova; City TB Hospital No. 2 (St. Petersburg): A. Panteleev (PI);
 305 Center for Prevention and Control of AIDS (Veliky, Novgorod): T. Trofimov (PI); Medical University
 306 Povoljskiy Federal Region.
- 307 Ukraine: Crimean Republican AIDS Centre (Simferopol): G. Kyselyova (PI).
- 308 **Western Europe:**
- 309 Denmark: Rigshospitalet (Cph): AB. Andersen (PI); Hvidovre University Hospital: K. Thorsteinsson.

310 Belgium: CHU Saint-Pierre (Brussels): MC Payen (PI), K. Kabeya and C. Necsoi.

311 France: Aquitaine Cohort. Cohort administration: F. Dabis (PI) and M. Bruyand. Participating Centers and
 312 Physicians: Bordeaux University Hospital: P. Morlat; Arcachon Hospital: A. Dupont; Dax Hospital: Y. Gerard;
 313 Bayonne Hospital: F. Bonnal; Libourne Hospital: J. Ceccaldi; Mont-de-Marsan Hospital: S. De Witte; Pau
 314 Hospital: E. Monlun; Périgueux Hospital: P. Lataste; Villeneuve-sur-Lot Hospital: I. Chossat.

315 Switzerland, Swiss HIV Cohort Study (SHCS, www.shcs.ch): Cohorte administration: M. Sagette and M.
 316 Rickenbach. Participating Centers and Physicians: University Hospital Basel: L. Elzi and M. Battegay;
 317 University Hospital Bern: H. Furrer (PI); Hopital Cantonal Universitaire, Geneve: D. Sculier and A. Calmy;
 318 Centre Hospitalaire Universitaire Vaudois, Lausanne: M. Cavassini; Hospital of Lugano: A. Bruno and E.
 319 Bernasconi; Cantonal Hospital St. Gallen: M. Hoffmann and P. Vernazza; University Hospital Zurich: J. Fehr
 320 and Prof. R. Weber. This study has been co-financed within the framework of the Swiss HIV Cohort Study,
 321 supported by the Swiss National Science Foundation (grant # 148522) and by SHCS project 666. The data
 322 are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36
 323 private physicians).The members of the Swiss HIV Cohort Study are: Aubert V, Battegay M, Bernasconi E,
 324 Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J,
 325 Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorgievski M, Günthard H (President
 326 of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C,
 327 Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B,
 328 Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A (Chairman of the Scientific Board), Regenass S,
 329 Rickenbach M (Head of Data Center), Rudin C (Chairman of the Mother & Child Substudy), Schöni-Affolter F,
 330 Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S.

331 United Kingdom: Mortimer Market Centre (London): R. Miller (PI) and N. Vora; St. Mary's Hospital: G.
 332 Cooke (PI) and S. Mullaney; North Manchester General Hospital: E. Wilkins (PI) and V. George; Sheffield
 333 Teaching Hospitals: P. Collini (PI) and D. Dockrell; King's College Hospital (London): F. Post (PI), L. Campbell,

334 R. Brum, E. Mabonga and P. Saigal. Queen Elizabeth Hospital: S. Kegg (PI); North Middlesex University
 335 Hospital: J. Ainsworth (PI) and A. Waters. Leicester Royal Infirmary: J. Dhar (PI) and L. Mashonganyika.

336 **Southern Europe:**

337 Italy: IRCCS - Ospedale L. Spallanzani (Rome): E. Girardi (PI), A. Rianda, V. Galati, C. Pinnetti and C. Tommasi;
 338 AO San Gerardo (Monza): G. Lapadula (PI); IRCCS AOU San Martino – IST di Genoa (Genova): A. Di Biagio (PI)
 339 and A. Parisini; Clinic of Infectious Diseases, University of Bari (Bari): S. Carbonara (PI), G. Angarano and M.
 340 Purgatorio; University of Brescia Spedali Civili: A. Matteelli (PI) and A. Apostoli.

341 Spain: Barcelona Cohort funded by the Spanish HIV/AIDS Research Network. Instituto de Salud Carlos III,
 342 Ministerio de Economía y Competitividad, Madrid (Spain) provided JMM a personal intensification research
 343 grant #INT15/00168 during 2016.: Hospital Clinic of Barcelona: J.M. Miro (PI), C. Manzardo, C. Ligeró and J.
 344 Gonzalez; Hospital del Mar: F. Sanchez, H. Knobel, M. Salvadó and J.L. Lopez-Colomes; Mutua de Terrassa:
 345 X. Martínez-Lacasa and E. Cuchí; Hospital Universitari Vall d'Hebrón: V. Falcó, A. Curran, M.T. Tortola, I.
 346 Ocaña and R. Vidal; Hospital Universitari de la Santa Creu i Sant Pau: MA. Sambeat, V. Pomar and P. Coll;
 347 Hospital Universitari de Bellvitge: D. Pozamczar, M. Saumoy and F. Alcaide; Agencia de Salud Pública de
 348 Barcelona: J. Caylà, A. Moreno, J.P. Millet, A. Orcau, L. Fina, L. del Baño, L.L. Roldan. Hospital Universitario
 349 Donostia (San Sebastian): JA. Iribarren (PI) and M. Ibarguren; Hospital Universitario Ramon y Cajal (Madrid):
 350 S. Moreno (PI) and A. González; Hospital Universitario 'Gregorio Marañón' (Madrid): P. Miralles (PI) and T.
 351 Aldámiz-Echevarría.

352 **Latin America**

353 The CICAL Cohort: Cohorte administration: M. Losso (PI), J. Toibaro and L. Gambardella. Participating
 354 Centers and Physicians: Argentina: Hospital J. M. Ramos Mejía (Buenos Aires): J. Toibaro and L. Moreno
 355 Macias; Hospital Paroissien (BA): E. Warley (PI) and S. Tavella; Hospital Piñero (BA): O. Garcia Messina and
 356 O. Gear; Hospital Nacional Profesor Alejandro Posadas: H. Laplume; Hospital Rawson (Cordoba): C. Marson
 357 (PI); Hospital San Juan de Dios (La Plata): J. Contarelia and M. Michaan; Hospital General de Agudos

358 Donación F. Santojani: P. Scapellato and D. D Alessandro; Hospital Francisco Javier Muñiz (BA): B. Bartoletti
359 and D. Palmero; Hospital Jujuy: C. Elias. Chile: Fundación Arriaran (Santiago): C. Cortes. México: INNcMZS
360 (México DF): B. Crabtree (PI); Hospital General Regional de Leon- CAPACITS: JL Mosqueda Gomez; Hospital
361 Civil de Guadalajara: A. Villanueva and LA Gonzalez Hernandez.

362

363 **TB:HIV Steering Committee**

364 H. Furrer, E. Girardi, J. A. Caylá, M. H. Losso, J. D. Lundgren, A. Panteleev (co-chair), R. Miller, J.M. Miro, Å.
365 B. Andersen, S. Tetradov, F. A. Post (co-chair), A. Skrahin and J. Toibaro.

366

367 **Statistical centre**

368 A. Schultze, A. Mocroft.

369

370 **Coordinating centre**

371 AM. W. Efsen, M. Mansfeld, B. Aagaard, B. R. Nielsen, A H. Fisher, E.V. Hansen, D. Raben, D. N. Podlekareva,
372 O. Kirk.

373 **Funding**

374 Funding: This work was supported by EU – 7th Framework (FP7/2007-2013, EuroCoord n 260694)
375 programme. The funding source had no role in study design, the collection, analysis and interpretation of
376 data; in the writing of the report; and in the decision to submit the article for publication.

377

378 **Disclosure of Potential Conflicts of Interest**

379

380 RFM reports personal fees from Gilead, ViiV, Merck, and Janssen outside the submitted work (non-
 381 promotional lectures on clinical aspects of HIV infection). JMM reports grants and personal fees from
 382 Abbvie, BMS, Cubist, Genentech, Gilead, Medtronik, MSD, Novartis, and ViiV Healthcare outside the
 383 submitted work. EG reports personal fees from Otsuka Novel products, Angelini, Gilead, Janssen outside
 384 the reported work. HJF reports grants from Abbvie, Gilead, MSD, BMS, ViiV, all paid to his institution
 385 outside the submitted work. OK reports personal fees and non-financial support from Gilead, personal fees
 386 from ViiV, non-financial support from Bristol Myers-Squibb outside the submitted work. All other authors
 387 report no conflict of interest.

388

389

References

- 390 1. World Health Organization. Global Tuberculosis Report 2015.
 391 http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf. Accessed 1 October 2017.
- 392 2. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis treatment
 393 and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. *Lancet*
 394 *Respir Med*. 2015;3(3):220-34.
- 395 3. Daley CL, Caminero JA. Management of multidrug resistant tuberculosis. *Semin Respir Crit*
 396 *Care Med*. 2013;34(1):44-59.
- 397 4. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution
 398 and transmission of drug-resistant tuberculosis in a Russian population. *Nat Genet*. 2014;46(3):279-86.
- 399 5. Acosta CD, Dadu A, Ramsay A, Dara M. Drug-resistant tuberculosis in Eastern Europe:
 400 challenges and ways forward. *Public Health Action*. 2014;4(Suppl 2):S3-S12.
- 401 6. Balabanova Y, Ignatyeva O, Fiebig L, Riekstina V, Danilovits M, Jaama K, et al. Survival of
 402 patients with multidrug-resistant TB in Eastern Europe: what makes a difference? *Thorax*. 2016.
- 403 7. Skrahina A, Hurevich H, Zalutskaya A, Sahalchik E, Astrauko A, Hoffner S, et al. Multidrug-
 404 resistant tuberculosis in Belarus: the size of the problem and associated risk factors. *Bull World Health*
 405 *Organ*. 2013;91(1):36-45.
- 406 8. Skrahina A, Hurevich H, Zalutskaya A, Sahalchik E, Astrauko A, van Gemert W, et al. Alarming
 407 levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. *Eur Respir J*. 2012;39(6):1425-
 408 31.
- 409 9. UNAIDS. AIDS by the numbers. WORLD AIDS DAY 2015.
 410 http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf. Accessed 1
 411 October 2017.
- 412 10. Yablonskii PK, Vizel AA, Galkin VB, Shulgina MV. Tuberculosis in Russia. Its history and its
 413 status today. *Am J Respir Crit Care Med*. 2015;191(4):372-6.
- 414 11. DeHovitz J, Uuskula A, El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. *Curr*
 415 *HIV/AIDS Rep*. 2014;11(2):168-76.
- 416 12. Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, et al. Major Challenges in
 417 Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and
 418 Latin America. *PLoS One*. 2015;10(12):e0145380.
- 419 13. Late presenters working group in CiE, Mocroft A, Lundgren J, Antinori A, Monforte A,
 420 Brannstrom J, et al. Late presentation for HIV care across Europe: update from the Collaboration of
 421 Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. *Euro Surveill*.
 422 2015;20(47).

- 423 14. Post FA, Grint D, Werlinrud AM, Panteleev A, Riekstina V, Malashenkov EA, et al. Multi-drug-
424 resistant tuberculosis in HIV positive patients in Eastern Europe. *J Infect.* 2014;68(3):259-63.
- 425 15. Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, et al.
426 Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international
427 cohort study. *Lancet HIV.* 2016;3(3):e120-31.
- 428 16. World Health Organization. Guidelines for the programmatic management of drug-resistant
429 tuberculosis 2011 update. http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf.
430 Accessed 1 October 2017.
- 431 17. Gunther G, Gomez GB, Lange C, Rupert S, van Leth F, Tbnnet. Availability, price and
432 affordability of anti-tuberculosis drugs in Europe: a TBNET survey. *Eur Respir J.* 2015;45(4):1081-8.
- 433 18. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, et al.
434 Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a
435 TBNET consensus statement. *Eur Respir J.* 2014;44(1):23-63.
- 436 19. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016
437 update. <http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf>. Accessed 1 October
438 2017.
- 439 20. Conradie F, Diacon A, Everitt D, Mendel C, Niekerk C et al. THE NIX-TB TRIAL OF
440 PRETOMANID, BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB. Abstract number 80LB. Oral presentation
441 from Conference on Retroviruses and Opportunistic Infections (CROI), 13-16 February 2017.
- 442 21. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant
443 pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis
444 of 9,153 patients. *PLoS Med.* 2012;9(8):e1001300.
- 445 22. Abubakar I, Zignol M, Falzon D, Ravigliione M, Ditiu L, Masham S, et al. Drug-resistant
446 tuberculosis: time for visionary political leadership. *Lancet Infect Dis.* 2013;13(6):529-39.
- 447 23. Strobe statement. <http://strobe-statement.org/index.php?id=strobe-home>. Accessed 1
448 October 2017..
- 449 24. World Health Organization. Treatment of tuberculosis guidelines fourth edition. 2010.
450 http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1. Accessed 1
451 October 2017.
- 452 25. Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, et al. Evaluation of a Rapid
453 Molecular Drug-Susceptibility Test for Tuberculosis. *N Engl J Med.* 2017;377(11):1043-54.
- 454 26. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based
455 resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a
456 multicountry surveillance project. *Lancet Infect Dis.* 2016;16(10):1185-92.
- 457 27. Gunther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, et al. Beyond multidrug-
458 resistant tuberculosis in Europe: a TBNET study. *Int J Tuberc Lung Dis.* 2015;19(12):1524-7.
- 459 28. Podlekareva D.N. SA, Panteleev A., Skrahina A.M., Miro J.M., Rakhmanova A., Furrer H.,
460 Miller R.F., Efsen A.M.W., Losso M.H., Toibaro J., Vassilenko A., Girardi E., Lundgren J.D., Mocroft A., Post
461 F.A., Kirk O., and the TB:HIV study in EuroCoord#. One-year mortality of HIV-positive patients treated for
462 rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America.
463 Accepted for publication in *AIDS*, November 2016.
- 464 29. Ahmad Khan F, Gelmanova IY, Franke MF, Atwood S, Zemlyanaya NA, Unakova IA, et al.
465 Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB. *Clin Infect Dis.*
466 2016.
- 467 30. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens
468 for multidrug-resistant tuberculosis reduce recurrence. *Clin Infect Dis.* 2013;56(6):770-6.
- 469 31. Velasquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, et al.
470 Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure
471 and death. *Clin Infect Dis.* 2014;59(1):9-15.

- 472 32. Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, et al. Major
473 differences in organization and availability of health care and medicines for HIV/TB coinfecting patients
474 across Europe. *HIV Med.* 2015;16(9):544-52.
- 475 33. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of
476 initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med.* 2010;362(8):697-706.
- 477 34. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later
478 start of antiretroviral therapy in HIV-infected adults with tuberculosis. *N Engl J Med.* 2011;365(16):1471-81.
- 479 35. Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of
480 Antiretroviral Therapy in Early Asymptomatic HIV Infection. *N Engl J Med.* 2015;373(9):795-807.
- 481 36. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of
482 antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med.* 2011;365(16):1482-91.
- 483 37. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic 2014.
484 <http://www.unaids.org/en/resources/documents/2017/90-90-90>. Accessed 1 October 2017.
- 485 38. Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, et al.
486 Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for
487 HIV co-infected patients in Lesotho. *PLoS One.* 2012;7(10):e46943.
- 488 39. Shin SS, Modongo C, Boyd R, Caiphus C, Kuate L, Kgwaadira B, et al. High Treatment Success
489 Rates among HIV-infected Multidrug-resistant Tuberculosis Patients after Expansion of Antiretroviral
490 Therapy in Botswana, 2006-2013. *J Acquir Immune Defic Syndr.* 2016.
- 491 40. Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS. Treatment outcomes in multidrug resistant
492 tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe
493 Tropical Disease Hospital Johannesburg, South Africa. *BMC Infect Dis.* 2015;15:478.
- 494 41. Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzeni EE, Ford N. Treatment outcomes for
495 HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. *Int J Tuberc Lung*
496 *Dis.* 2015;19(8):969-78.
- 497 42. Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, et al. Short- and long-
498 term mortality and causes of death in HIV/tuberculosis patients in Europe. *Eur Respir J.* 2014;43(1):166-77.
- 499 43. Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment
500 among hospitalized opioid dependent patients in Ukraine. *Int J Drug Policy.* 2013;24(6):e91-8.

501

502

503

Figure 1: TB treatment and outcomes over time among 105 patients with MDR-TB (left), 183 with no DST (middle) and 130 patients with susceptible TB (right) from time of start of TB treatment.

506

507 *R = Rifampicin*
 508 *H = Isoniazid*
 509 *Z = Pyrazinamide*
 510 *E = Ethambutol*
 511 *S = Streptomycin*
 512 *FQ = Fluoroquinolone*
 513 *2L-inj = Second-line injectables*
 514 *LTFU = Loss to follow-up*
 515 *DST = Drug-susceptibility test*
 516

517 **Figure 2a-c: Number of *total* TB drugs (a), *potentially active** (b), and *known active*** (c) TB drugs at each time point for 105 MDR-TB**
 518 **patients under follow-up.**

519 *Potentially active: Assuming susceptibility where DST for a specific drug was missing.

520 **Known active: Only including known DST results and not assuming susceptibility for missing DST.

2b: Months since TB diagnosis

2c: Months since TB diagnosis

526 Figure 3. Antiretroviral (ART) status over time for MDR-TB patients (N=105)*

*ART and viral load (VL) was calculated +/- 1 month of the various time-points.

530
531 Table 1. Baseline characteristics of the included individuals (N=485)

		Total	MDR-TB*	All other groups	p ⁷
		N (%)	N (%)	N (%)	
Total		485	105	380	
Gender	<i>Male</i>	374 (77)	84 (80)	290 (76)	0.43
Ethnicity¹	<i>White</i>	442 (94)	98 (96)	344 (94)	0.42
Previous TB²	<i>Yes</i>	64 (13)	24 (23)	40 (11)	<0.01
TB risk factors	<i>Prison</i>	91 (19)	22 (21)	69 (18)	0.52
	<i>Alcohol</i>	128 (26)	30 (29)	98 (26)	0.57
	<i>Family</i>	41 (8)	12 (11)	29 (8)	0.22
	<i>Travel</i>	0	0	0	N/A
Injection drug use (ever)	<i>Yes</i>	327 (67)	80 (76)	247 (65)	0.03
OST (ever)	<i>Yes</i>	6 (1)	0 (0)	6 (2)	0.32
Hepatitis C³	<i>Yes</i>	254 (52)	59 (56)	195 (51)	0.03
TB type	<i>Pulmonary</i>	176 (36)	45 (43)	131 (34)	0.27
	<i>Extra pulmonary</i>	24 (5)	4 (4)	20 (5)	
	<i>Disseminated</i>	285 (59)	56 (53)	229 (60)	
HIV+ >3 months before TB diagnosis	<i>Yes</i>	354 (73)	81 (77)	273 (72)	0.28
ART⁷	<i>Yes</i>	82 (17)	14 (13)	68 (18)	0.27
		Median (IQR)			
Age	<i>Year</i>	35 (31-40)	35 (31-40)	35 (31-40)	0.75
Weight⁴	<i>Kg</i>	60 (53-68)	63 (55-68)	59 (53-68)	0.29
CD4 cell count⁵	<i>(cells/mm3)</i>	91 (31-230)	100 (32-267)	89 (31-220)	0.59
HIV-RNA⁶	<i>Log10 copies/ml</i>	5.25 (4.40-5.75)	5.42 (4.46-5.91)	5.22 (4.35-5.70)	0.13

532 1. 9 individuals had missing data on previous TB.

533 2. 17 individuals had missing data on ethnicity.

534 3. 148 individuals had missing data on hepatitis C.

535 4. 300 individuals had missing weight at baseline.

536 5. 87 individuals had missing baseline CD4.

537 6. 211 individuals had missing baseline HIV-RNA.

538 7. P-values compare the characteristics between individuals with MDR-TB and all other individuals included in the study. The chi-squared test, fisher's exact test, or Mann-Whitney u
539 test was used as appropriate.

540 OST = Opioid substitution therapy.

541 ART = antiretroviral therapy.

542 Table 2. Results from drug susceptibility test performed at any time point in follow-up among all patients with
 543 MDR-TB (N=105)

Drug	<u>N (%) with data</u>	<u>N (% of those tested) with resistance</u>
Group 1		
Pyrazinamide	54 (51)	30 (56)
Ethambutol	100 (95)	72 (72)
Streptomycin	75 (71)	72 (96)
Group 2		
Fluoroquinolones	79 (75)	22 (28)
Group 3		
Second-line injectables	82 (78)	35 (43)
Group 4		
Ethionamide/Prothionamide	72 (69)	23 (32)
Cycloserine/Terizidone	51 (49)	8 (16)
Para-Aminosalicylic Acid (PAS)	61 (58)	10 (16)

547 **Table 3. DST performance and TB drug use among patients with MDR-TB (N=105)**

3a: N (%) of patients who had DST performed per drug up to the indicated time point among those under follow-up at given time point

	N	R	H	Z	E	FQ	2L-inj	PT/ET	CS/TZ	PAS	BDQ	DLM	LNZ
0	105	49 (47)	49 (47)	27 (26)	46 (44)	35 (33)	37 (35)	32 (30)	16 (15)	24 (23)	0	0	0
1 month	88	88 (100)	88 (100)	47 (53)	82 (93)	63 (72)	66 (75)	57 (65)	40 (45)	47 (53)	0	0	0
2 months	79	79 (100)	79 (100)	44 (56)	74 (94)	58 (73)	64 (81)	54 (68)	40 (51)	45 (57)	0	0	0
3 months	72	72 (100)	72 (100)	40 (56)	68 (94)	54 (75)	61 (85)	51 (71)	37 (51)	41 (57)	0	0	0
7 months	56	56 (100)	56 (100)	42 (57)	53 (95)	43 (77)	47 (84)	40 (71)	30 (54)	33 (59)	0	0	0
13 months	44	44 (100)	44 (100)	25 (57)	42 (95)	35 (80)	37 (84)	30 (70)	22 (50)	26 (59)	0	0	0
21 months	31	31 (100)	31 (100)	16 (52)	29 (94)	23 (74)	25 (81)	23 (74)	16 (52)	22 (71)	0	0	0

3b: N (%) of patients under follow-up who received selected anti-TB medications at the indicated time point

	N	R	H	Z	E	FQ	2L-inj	PT/ET	CS/TZ	PAS	BDQ	DLM	LNZ
0	105	86 (82)	89 (85)	90 (86)	84 (80)	16 (15)	23 (22)	14 (13)	10 (10)	4 (4)	0	0	0
1 month	88	57 (65)	59 (67)	76 (86)	68 (77)	32 (36)	38 (43)	31 (35)	23 (26)	17 (19)	0	0	0
2 months	79	39 (49)	37 (47)	66 (84)	53 (67)	43 (54)	46 (58)	40 (51)	30 (38)	29 (34)	0	0	0
3 months	72	23 (32)	23 (32)	55 (76)	37 (51)	51 (71)	48 (67)	49 (68)	39 (54)	33 (46)	0	0	0
7 months	56	6 (11)	5 (9)	42 (75)	21 (38)	50 (89)	39 (70)	47 (84)	37 (66)	31 (55)	0	0	1 (2)
13 months	44	5 (11)	4 (9)	34 (77)	14 (32)	39 (89)	15 (34)	33 (75)	27 (61)	20 (45)	0	0	0
21 months	31	2 (6)	1 (3)	20 (65)	7 (23)	25 (81)	8 (26)	19 (61)	22 (71)	15 (48)	0	0	0

3c: N (%) of patients under follow-up who had ever received selected TB medications at the indicated time point

	N	R	H	Z	E	FQ	2L-inj	PT/ET	CS/TZ	PAS	BDQ	DLM	LNZ
0	105	86 (82)	89 (85)	90 (86)	84 (80)	16 (15)	23 (22)	14 (13)	10 (10)	4 (4)	0	0	0
1 month	88	76 (86)	75 (85)	81 (92)	76 (86)	33 (38)	40 (45)	32 (36)	23 (26)	17 (19)	0	0	0
2 months	79	68 (86)	66 (84)	72 (91)	68 (86)	45 (60)	49 (62)	41 (52)	31 (39)	29 (37)	0	0	0
3 months	72	62 (86)	61 (85)	66 (92)	61 (85)	54 (75)	55 (76)	51 (71)	40 (56)	36 (50)	0	0	0
7 months	56	47 (84)	47 (84)	53 (95)	51 (91)	51 (91)	49 (88)	48 (86)	40 (71)	33 (59)	0	0	1 (2)
13 months	44	39 (89)	39 (89)	42 (95)	42 (95)	40 (91)	38 (86)	37 (84)	31 (70)	24 (55)	0	0	0
21 months	31	27 (87)	27 (87)	29 (94)	30 (97)	29 (94)	28 (90)	26 (84)	23 (74)	20 (65)	0	0	0

548 *DST = Drug Susceptibility Test*549 *R = Rifampicin*

- 550 *H = Isoniazid*
- 551 *Z = Pyrazinamide*
- 552 *E = Ethambutol*
- 553 *FQ = Fluoroquinolone*
- 554 *2L-inj = Second-line injectables*
- 555 *PT/ET = Prothionamide/Ethionamide*
- 556 *CS/TZ = Cycloserine/Terizidone*
- 557 *PAS = Para-aminosalicylic acid*
- 558 *BDQ = Bedaquiline*
- 559 *DLM = Delamanide*
- 560 *LNZ = Linezolid*
- 561

562 Box:

563 **Definitions of tuberculosis resistance**

	Definition
Multidrug-resistant tuberculosis (MDR-TB)	Tuberculosis resistant to rifampicin and isoniazid
Pre-extensively drug-resistant tuberculosis (pre-XDR-TB)	MDR-TB plus additional resistance against a fluoroquinolone <i>or</i> a second-line injectable
Extensively drug-resistant tuberculosis (XDR-TB)	MDR-TB plus additional resistance against a fluoroquinolone and a second-line injectable

564

565